Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapansutrile in acute gout flare
NCT05658575Phase 3Recruiting
- Sponsor
- Olatec Therapeutics LLC
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in acute gouty arthritis comparing Dapansutrile with Placebo (2 arms). Primary endpoint: Joint pain reduction at 72 hours. Started Jan 2023; status: recruiting.
02
Drugs
dapansutrile
03
Conditions
acute gouty arthritis
Beyond the preview
Go deeper on NCT05658575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05658575.